Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
IRF3 和 RXRa 串扰在宿主对病毒感染的反应中的作用
基本信息
- 批准号:8091282
- 负责人:
- 金额:$ 36.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcetaminophenAcute Liver FailureAffectAgonistAmericasAntiviral AgentsAntiviral ResponseAspirinBiologicalCellsCellular Metabolic ProcessChemosensitizationChildCytochrome P450DataDiseaseFamily memberGene TargetingGenesGoalsHealthHepatocyteHepatotoxicityHormonesHost DefenseImmuneImmune responseInfectionInjuryInterferon Type IInvadedInvestigationKnockout MiceLeadLiverLiver diseasesMediatingMetabolicMetabolic DiseasesMetabolismMethodsModelingMolecularNatureNuclearNuclear Hormone ReceptorsNuclear Receptor GeneNuclear ReceptorsPathogenesisPathway interactionsPatientsPharmaceutical PreparationsProteomicsRXRRepressionReye SyndromeRoleSignal PathwaySignaling MoleculeTissue TransplantationTissuesToll-like receptorsToxic effectTylenolVesicular stomatitis Indiana virusViralViral PathogenesisVirusVirus Diseasescell typedrug metabolismdrug modificationgene repressionhuman IRF3 proteinimmunoregulationinterferon regulatory factor-3mouse modelnovelnovel strategiespathogenpreventprograms
项目摘要
DESCRIPTION (provided by applicant): The long term goal of this application is to elucidate the mechanisms and biological significance of crosstalk between the innate immune response and nuclear hormone receptors in host defense against infections and in pathogen-associated metabolic diseases. Preliminary data in our lab has identified a novel Interferon Regulatory Factor 3(IRF3)-dependent but type I interferon independent pathway induced during innate immune response to viral product stimulation or viral infection, leading to strong transcriptional repression of Retinoid X Receptor 1 (RXR1). As RXR1 is the major heterodimer partner for most of the nuclear hormone receptors involved in numerous cellular metabolic processes, we hypothesize that repression of RXR1 and its regulated genes during viral infections can have strong impacts on host metabolisms especially drug metabolisms. We further suggest this can contribute to the pathogenesis of viral associated metabolic diseases such as Reye's Syndrome, a hepatotoxicity disease that occurs when children are given aspirin in the context of a viral infection, or acetaminophen (APAP)-induced hepatotoxicity, which accounts for about half of the acute liver failures in US. Interestingly, our preliminary studies indicate that innate immune responses to viral products can potentiate aspirin-induced but protect APAP-induced hepatotoxicity, which may explain why during viral infections patients are safer to use Tylenol than Aspirin. These results further suggest that, depending upon the nature of the drugs, viral infections may differentially affect the accumulation of the drug's intermediate metabolites, which could lead to opposite toxic effects on host tissues. In this application, we will first develop mouse models that mimic Reye's Syndrome and acetaminophen (APAP)-induced hepatotoxicity. We will then use these two opposite drug metabolism models as examples to determine how innate immune responses to viral infection could differentially alter stability or toxicity of different drugs. Furthermore, additional preliminary data in our lab showed that nuclear hormone receptor agonists can suppress the induction of antiviral genes and promote viral replications. We therefore also hypothesize that repression of nuclear hormone receptors by the innate immune response may contribute to an effective anti-viral response. We will further analyze the effects of nuclear hormone receptors and their agonists on anti-viral innate immune responses to determine if the repression of nuclear hormone receptors by innate immune response is necessary for the proper host defense against viral infections. We believe our investigation of the crosstalk between the innate immune response and nuclear hormone receptor-mediated metabolism will not only help us to understand the mechanisms responsible for virally induced metabolic diseases and drug induced immuno-suppressions but will also provide novel strategies to prevent or treat patients with viral infections and their associated metabolic diseases. PUBLIC HEALTH RELEVANCE: Numerous diseases including metabolic diseases are associated with virus infections. On the other hand, many metabolic products and drugs can also affect our body's ability to defend against invading viruses. However, the molecular mechanisms responsible for such associations are not clear. We recently found a novel crosstalk between host immune response and metabolisms, which could explain not only viral associated liver diseases such as Reye's Syndrome but also how metabolic drugs can inhibit host response against viral infections. Further investigation on such crosstalk will provide novel strategies to prevent or treat patients with viral infections and their associated metabolic diseases such as acetaminophen (APAP)-induced hepatotoxicity, which accounted for about half of all acute liver failures in America.
描述(由申请人提供):本申请的长期目标是阐明宿主防御感染和病原体相关代谢疾病中先天免疫应答与核激素受体之间串扰的机制和生物学意义。我们实验室的初步数据已经确定了一种新的干扰素调节因子3(IRF3)依赖性,但I型干扰素非依赖性途径诱导先天免疫反应的病毒产物刺激或病毒感染,导致强烈的转录抑制类维生素A X受体1(RXR 1)。由于RXR 1是参与许多细胞代谢过程的大多数核激素受体的主要异源二聚体伴侣,我们假设在病毒感染期间RXR 1及其调控基因的抑制可以对宿主代谢特别是药物代谢产生强烈影响。我们进一步表明,这可能有助于病毒相关代谢疾病的发病机制,如Reye综合征,一种肝毒性疾病,当儿童在病毒感染的背景下服用阿司匹林时发生,或对乙酰氨基酚(APAP)诱导的肝毒性,约占美国急性肝功能衰竭的一半。有趣的是,我们的初步研究表明,对病毒产物的先天免疫反应可以增强阿司匹林诱导的肝毒性,但保护APAP诱导的肝毒性,这可以解释为什么在病毒感染期间,患者使用泰诺比阿司匹林更安全。这些结果进一步表明,根据药物的性质,病毒感染可能会不同程度地影响药物中间代谢产物的积累,这可能导致对宿主组织的相反毒性作用。在本申请中,我们将首先开发模拟Reye综合征和对乙酰氨基酚(APAP)诱导的肝毒性的小鼠模型。然后,我们将使用这两个相反的药物代谢模型作为例子,以确定如何先天免疫反应病毒感染可以差异改变不同药物的稳定性或毒性。此外,我们实验室的其他初步数据表明,核激素受体激动剂可以抑制抗病毒基因的诱导并促进病毒复制。因此,我们还假设,抑制核激素受体的先天免疫反应可能有助于有效的抗病毒反应。我们将进一步分析核激素受体及其激动剂对抗病毒先天免疫应答的作用,以确定先天免疫应答对核激素受体的抑制是否是宿主对抗病毒感染的适当防御所必需的。我们相信我们对先天免疫应答和核激素受体介导的代谢之间的串扰的研究不仅有助于我们理解病毒诱导的代谢疾病和药物诱导的免疫抑制的机制,而且还将提供预防或治疗病毒感染及其相关代谢疾病的新策略。公共卫生相关性:包括代谢性疾病在内的许多疾病都与病毒感染有关。另一方面,许多代谢产物和药物也会影响我们身体抵御入侵病毒的能力。然而,负责这种协会的分子机制尚不清楚。我们最近发现了宿主免疫反应和代谢之间的一种新的串扰,这不仅可以解释病毒相关的肝脏疾病,如Reye综合征,还可以解释代谢药物如何抑制宿主对病毒感染的反应。对这种串扰的进一步研究将为预防或治疗病毒感染及其相关代谢性疾病(如对乙酰氨基酚(APAP)诱导的肝毒性)患者提供新的策略,这些疾病约占美国所有急性肝衰竭的一半。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GENHONG CHENG其他文献
GENHONG CHENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GENHONG CHENG', 18)}}的其他基金
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 36.75万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 36.75万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10461773 - 财政年份:2020
- 资助金额:
$ 36.75万 - 项目类别:
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
ZIKV 母婴传播的遗传进化、发病机制和免疫反应
- 批准号:
10388193 - 财政年份:2018
- 资助金额:
$ 36.75万 - 项目类别:
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
ZIKV 母婴传播的遗传进化、发病机制和免疫反应
- 批准号:
9925059 - 财政年份:2018
- 资助金额:
$ 36.75万 - 项目类别:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
非典型 NF-kB 激活的 IKKa 依赖性负反馈控制
- 批准号:
8039043 - 财政年份:2011
- 资助金额:
$ 36.75万 - 项目类别:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
非典型 NF-kB 激活的 IKKa 依赖性负反馈控制
- 批准号:
8208992 - 财政年份:2011
- 资助金额:
$ 36.75万 - 项目类别:
Mitiagrion of Radiation Damage by Mechanisms of Innate Immune Regulation
通过先天免疫调节机制减轻辐射损伤
- 批准号:
8011751 - 财政年份:2010
- 资助金额:
$ 36.75万 - 项目类别:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
IRF3 和 RXRa 串扰在宿主对病毒感染的反应中的作用
- 批准号:
7741382 - 财政年份:2009
- 资助金额:
$ 36.75万 - 项目类别:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
IRF3 和 RXRa 串扰在宿主对病毒感染的反应中的作用
- 批准号:
8481502 - 财政年份:2009
- 资助金额:
$ 36.75万 - 项目类别:
相似国自然基金
SirT1在Acetaminophen诱发的药物性肝损伤中的作用及机制
- 批准号:81100281
- 批准年份:2011
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of microRNA_21 in acetaminophen-induced acute liver failure
microRNA_21在对乙酰氨基酚诱导的急性肝衰竭中的作用
- 批准号:
9433645 - 财政年份:2017
- 资助金额:
$ 36.75万 - 项目类别:
Functional role of macrophage subsets in acetaminophen-induced acute liver failure and therapeutic implica-tions of its modulation by chemokine pathways
巨噬细胞亚群在对乙酰氨基酚诱导的急性肝衰竭中的功能作用及其通过趋化因子途径调节的治疗意义
- 批准号:
286463944 - 财政年份:2015
- 资助金额:
$ 36.75万 - 项目类别:
Research Grants
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
9886668 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
9040935 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
8826109 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
8482328 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
8619622 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
10320929 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
9249528 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
- 批准号:
10077553 - 财政年份:2013
- 资助金额:
$ 36.75万 - 项目类别: